New Zealand invests to boost number of smear tests:
This article was originally published in Clinica
Executive Summary
New Zealand is investing NZ$2.5m (US$1.8m) in an awareness drive aimed at increasing the number of women having cervical smears and to encourage regular testing in the 20-70 year age range. Prime Minister Helen Clark said that early detection through smears was the main reason behind a significant reduction in cervical cancer deaths in New Zealand - from 180 per year 10 years ago, to 70. Screening reduces the risk of developing cervical cancer by 90%, according to the national screening unit. The disease is treatable if caught early enough, but the catch is that it usually has no symptoms. The awareness campaign is targeted mainly at Maori and Pacific Island women, who have the lowest screening and the highest incidence rates of cervical cancer in New Zealand, but is also expected to encourage women in the wider population who have not been screened in the last three years, to come forward.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.